Eli Lilly & Co. (LLY)

1155.00 -19.61 (-1.67%) USD  |  NYSE  |  Aug 31, 14:32
More

Eli Lilly Total Long Term Debt (Quarterly) : 49.62B for June 30, 2026

Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for LLY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 49.62B
March 31, 2026 41.60B
December 31, 2025 43.64B
September 30, 2025 42.51B
June 30, 2025 39.90B
March 31, 2025 38.52B
December 31, 2024 33.64B
September 30, 2024 31.12B
June 30, 2024 28.89B
March 31, 2024 26.21B
December 31, 2023 25.23B
September 30, 2023 20.17B
June 30, 2023 18.82B
March 31, 2023 18.88B
December 31, 2022 16.24B
September 30, 2022 15.89B
June 30, 2022 16.81B
March 31, 2022 16.51B
December 31, 2021 16.88B
September 30, 2021 17.09B
June 30, 2021 16.52B
March 31, 2021 16.20B
December 31, 2020 16.60B
September 30, 2020 16.33B
June 30, 2020 15.06B
Date Value
March 31, 2020 13.98B
December 31, 2019 14.31B
September 30, 2019 15.71B
June 30, 2019 16.29B
March 31, 2019 16.47B
December 31, 2018 9.800B
September 30, 2018 12.68B
June 30, 2018 12.22B
March 31, 2018 11.70B
December 31, 2017 10.95B
September 30, 2017 13.46B
June 30, 2017 12.31B
March 31, 2017 10.25B
December 31, 2016 9.006B
September 30, 2016 9.349B
June 30, 2016 9.331B
March 31, 2016 8.126B
December 31, 2015 7.978B
September 30, 2015 8.079B
June 30, 2015 7.999B
March 31, 2015 7.631B
December 31, 2014 5.376B
September 30, 2014 5.306B
June 30, 2014 5.301B
March 31, 2014 5.255B

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Johnson & Johnson 37.34B
Merck & Co., Inc. 51.08B
Pfizer Inc. 63.10B
Bristol Myers Squibb Co. 44.59B
Atai Beckley, Inc. 1.571M